Watpac Limited (ASX: WTP) has been awarded a $83 million contract from the Australian Nuclear Science and Technology Organisation to design and construct the Nuclear Medicine Molybdenum-99 facility in Lucas Heights, New South Wales.
The new 4,250 square metre high-tech facility will supply critical life-saving radioisotope Molybdenum-99 to healthcare providers throughout Australia and overseas.
ANSTO has been producing Molybdenum-99 – an active pharmaceutical ingredient used in more than 45 million nuclear medicine diagnostic procedures each year worldwide – for about 40 years and provides half a million doses per annum.
Design work will begin in February 2014 and construction is scheduled for completion in early 2016.
The building is classified as a nuclear installation and will be designed to meet the requirements of the Australian Radiation Protection and Nuclear Safety Agency and Australian Non-proliferation and Safeguards Office.
Watpac’s other current projects include the $148 million Gold Coast Private Hospital, the $65 million Port Macquarie Base Hospital Expansion Project in New South Wales and the $40 million Phase 3 of the Queensland Institute of Medical Research in Brisbane.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.